Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 23, 2025LifeOpen Access

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

View Full Paper
Ask AI
Bookmark
Share

Authors

CLCaspar LiesenhoffCMCarolin MeyrlDKDaniel J. Krause

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Liesenhoff et al. (2025) studied this question.

synapsesocial.com/papers/6a9592162fdd6c151ff24915https://doi.org/10.3390/life15111657
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ranibizumab for Neovascular Age-Related Macular Degeneration2006 · 5,928 citations
  2. 2Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept2024 · 10 citations
  3. 3Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration2024 · 21 citations
  4. 4Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment2020 · 153 citations
  5. 5Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration2023 · 112 citations